BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting
April 02, 2017 13:16 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass., April 02, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for...
BeiGene Announces Presentation of Phase IB Data on BGB-283 at the 2017 American Association for Cancer Research Annual Meeting
March 02, 2017 09:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for...